After-Hours Buzz: Hewlett-Packard, JC Penney, Tesla & More
Pharmaceuticals Biotechnology and Life Sciences
More
-
Patients given drug-coated stents after an acute heart attack are nearly five times more likely to die six months to two years later than those with bare metal forms of the arterial scaffolding, research showed on Tuesday.
-
A U.S. court dismissed some claims in a lawsuit filed by Johnson & Johnson over its failed bid for Guidant.
-
Schering-Plough and Merck Tuesday said U.S. regulators had accepted the marketing application for their experimental allergy drug, which combines two widely used existing treatments into a single tablet.
-
Pfizer on Wednesday said it named Frank A. D'Amelio, a senior executive of Alcatel-Lucent, as chief financial officer of the drugmaker.
-
Shares of Dendreon rose Monday after the company said its breast cancer drug was effective in an early stage clinical trial.
-
On Amgen's conference call the other day regarding the biotech company's cutbacks, officials repeatedly stated that they think the federal government's new, restrictive guidelines for use and payment of Amgen's bread-and-butter anemia drugs will hurt patients and specifically, result in the need for more risky, old-fashioned blood transfusions to treat the condition.
-
Amgen shares plunged to a 52-week low on Thursday in the wake of the biotechnology firm’s announcement that it will lay off more than 2,000 and as many as 2,600 employees--or 12 percent to 14 percent of its labor force.
-
Syneron Medical just reported a great quarter, but it was down Tuesday nonetheless. What's going on?Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
A rebound in the financial sector and positive earnings surprises triggered gains for some of the most actively traded stocks on Tuesday.
-
Corporate news and analyst upgrades were some of the catalysts behind the most actively traded stocks on Monday.
-
Earnings reports and corporate announcements were some of the catalysts behind the most actively traded stocks on Tuesday.
-
Earnings reports and corporate announcements were some of the catalysts behind the most actively traded stocks on Monday.
-
As the push for universal health care in the U.S. heats up on Capitol Hill, market experts say generic drug stocks and pharmaceutical distributors should perform well, while the hit to big pharma may not be as bad as some anticipate.
-
M&A news and stock buybacks were some of the catalysts behind the most actively traded stocks on Friday.
-
Despite Thursday’s massive drop, there are still stocks worth buying. Cramer lays out the best type to own.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Sepracor posted lower-than-expected results Friday and cut its 2007 outlook amid competition for its insomnia drug and reduced reimbursement for its asthma drug, sending its shares down 20 percent.
-
Amgen outstripped Wall Street's earnings expectations with a second-quarter profit of $1.12 a share. Sales came in at $3.73 billion, also higher than consensus forecasts. The company also said its most important experimental drug, denosumab, met all its goals in a pivotal clinical trial of breast cancer patients.
-
Quarterly earnings reports and new drug trial data were some of the catalysts behind the most actively traded stocks on Wednesday.
-
U.S. regulators should wait for final survival data before deciding whether to approveGPC Biotech proposed prostate cancer pill Orplatna, an advisory panel said on Tuesday in a 12-0 vote.
-
Quarterly earnings reports and corporate alliances were some of the catalysts behind the most actively traded stocks on Tuesday.